Last reviewed · How we verify
Custirsen, paclitaxel and carboplatin
Custirsen, paclitaxel and carboplatin is a Small molecule drug developed by Achieve Life Sciences. It is currently in Phase 1 development.
At a glance
| Generic name | Custirsen, paclitaxel and carboplatin |
|---|---|
| Sponsor | Achieve Life Sciences |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Custirsen, paclitaxel and carboplatin CI brief — competitive landscape report
- Custirsen, paclitaxel and carboplatin updates RSS · CI watch RSS
- Achieve Life Sciences portfolio CI
Frequently asked questions about Custirsen, paclitaxel and carboplatin
What is Custirsen, paclitaxel and carboplatin?
Custirsen, paclitaxel and carboplatin is a Small molecule drug developed by Achieve Life Sciences.
Who makes Custirsen, paclitaxel and carboplatin?
Custirsen, paclitaxel and carboplatin is developed by Achieve Life Sciences (see full Achieve Life Sciences pipeline at /company/achieve-life-sciences).
What development phase is Custirsen, paclitaxel and carboplatin in?
Custirsen, paclitaxel and carboplatin is in Phase 1.